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Mol and gp160-gp93 are two surface membrane glycoprotein heterodimers present on granulocytes and 
monocytes derived from humans and guinea pigs, respectively. We purified both antigens and found that 
their alpha subunits had identical N-termini which were significantly homologous to the alpha subunit of the 
human adhesion platelet glycoprotein IIb/IIIa. 
Mol is a surface glycoprotein heterodimer pre- 
sent on human granulocytes, monocytes/  
macrophages and null cells [1]. It consists of an 
alpha chain of apparent molecular mass of 
155-165 kDa noncovalently linked to a beta chain 
of 94 kDa [2]. The beta chain is shared by two 
other leukocyte surface antigens, a lymphocyte- 
function-associated antigen, LFA-1 (alpha subunit 
180 kDa) and the Leu M5 (p 150, 95) antigen 
(alpha subunit 130-150 kDa) [3-5]. Mol is identi- 
cal with complement receptor type 3 (CR3) [6,7] 
and also promotes adhesion of granulocytes to 
each other [8] and to endothelial cell monolayers 
[9]. The biologic significance of the M o l / L F A - 1 /  
Leu M5 glycoprotein family is underscored by the 
finding that genetic deficiency of all three mole- 
cules in man results in recurrent and life-threaten- 
ing bacterial infections and is associated with 
abnormal leukocyte adhesion-dependent functions 
such as phagocytosis, chemotaxis, adhesion to en- 
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dothelial cells, leukoaggregation, T cell-mediated 
cytotoxicity and natural killing [10,11]. 
To gain more insight into the structure-function 
relationship, we purified human Mol to homo- 
geneity from normal granulocytes by affinity chro- 
matography and high-performance liquid chro- 
matography (HPLC) and determined the N-termi- 
nal amino acid sequence of its alpha subunit 
(Mol). The obtained sequence was identical, ex- 
cept for two conservative substitutions, to that of 
the alpha subunit of Mac-1 antigen [12] and to 
gp160, the large subunit of gp160-gp93, a major 
guinea-pig granulocyte/macrophage glycoprotein 
heterodimer [13-15] of hitherto unknown function 
which we also purified by affinity chromatogra- 
phy. Significantly, the N-terminal amino acid se- 
quence of Mol~ was homologous to that of the 
alpha subunit of platelet glycoprotein IIb/IIIa 
[16]. The results of our study provide evidence for 
the evolutionary conservation of M o l .  The ho- 
mology of its N-terminal amino acid sequence to 
the alpha subunit of IIb/IIIa, a glycoprotein that 
subserves similar adhesion functions on platelets, 
suggest that additional homologies between ad- 
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hes ion  r ecep to r s  on  d i f f e ren t  cell  types  such as 
g r a n u l o c y t e s / m a c r o p h a g e s ,  p la te le t s ,  l y m p h o -  
cy tes  and  f ib rob las t s  m a y  exist.  
M o l  was  pu r i f i ed  f r o m  h u m a n  g r anu locy t e s  by  
a f f in i ty  c h r o m a t o g r a p h y  us ing  a n t i - M o l  m o n o -  
c lona l  a n t i b o d y  [1] cova l en t l y  l i nked  to S e p h a r o s e  
4B ( P h a r m a c i a ,  Sweden )  [17], fo l lowed  by  high-  
p e r f o r m a n c e  l iqu id  c h r o m a t o g r a p h y  ( H P L C )  (see 
l egend  to Fig.  1). G p 1 6 0 - g p 9 3 ,  a m a j o r  t ryps in-  
a n d  p l a smin - sens i t i ve  sur face  g l y c o p e p t i d e  he te ro -  
d i m e r  of  g u i n e a - p i g  g ranu locy te s  a n d  m a c r o -  
p h a g e s  [13-15]  was  pu r i f i ed  by  len t i l - lec t in  sep-  
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h a r o s e  a n d  m o n o c l o n a l  a n t i b o d y - S e p h a r o s e  a f f in-  
i ty  c h r o m a t o g r a p h y  ( l egend  to Fig.  1). W h e n  c o m -  
p a r e d  to each  o ther ,  and  to  m u r i n e  Mac-1  an t igen  
[12], it is a p p a r e n t  tha t  Mol,~,  M a c - l , ,  and  g p l 6 0  
h a v e  iden t i ca l  N - t e r m i n a l  p r i m a r y  s t ruc tures .  Sub-  
s t i tu t ions  in a va r i ab l e  r eg ion  at  cycles  7 - 9  are  all 
c o n s e r v a t i v e  as de f i ned  by  the  m u t a t i o n  d a t a  ma-  
t r ix  of  D a y h o f f  [22]. These  d a t a  p r o v i d e  e v i d e n c e  
fo r  the  c o n s e r v a t i o n  o f  the  M o l  an t i gen  across  
th ree  species,  r e f l ec t ing  its i m p o r t a n t  b io log ic  
func t ions .  
T h e  N - t e r m i n a l  s equence  o f  h u m a n  M o l ~ ,  h a d  
Human Mol 
Cuinea pig gp160 
Mouse Mac-I fl 
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Fig. 1. N-terminal amino acid sequence of human Mol,, and guinea-pig gp160. Human granulocytes were purified by Ficol-Hypaque 
centrifugation of anticoagulated whole blood [18]. Purified ceils were treated with diisopropylfluorophosphate (DFP) (5 mM end 
concentration) at (0.5-1). 10S/ml in phosphate-buffered saline for 10 min at 0°C. The cells were washed once and then solubilized in 
phosphate-buffered saline (pH 7.4), containing 2 mM phenylmethylsulfonylfluoride (PMSF) and 0.5% detergent (NP40 or Triton 
X-100) for 10 min at 4°C. Following centrifugation at 100000x g for 30 min at 4°C, the supernatant was collected and used as a 
source of antigen. Mol was isolated from human granulocyte lysate by affinity chromatography followed by high-performance liquid 
chromatography as follows. 20 ml of anti-Mol Sepharose 4B (2-4 mg of antibody per ml) is poured into a 50 ml column and 
equilibrated with phosphate-buffered saline. The granulocyte lysate (3.10 9 cell equivalents in 30 ml) is diluted up to 90 ml in 
phosphate-buffered saline containing 2 mM PMSF and 0.25% NP40 and passed slowly through the column at a flow rate of about 
6-8 ml/h, at 4°C. The column is then washed with 100 ml of the equilibration buffer, 50 ml of 20 mM glycine buffer (pH 9) and 50 
ml of 20 mM glycine buffer (pH 10) each containing 0.1% NP40. Mol is then desorbed with 20 mM glycine (pH 11.5) containing 
0.5% NP40, 2 mM PMSF and 1 mM iodoacetic acid. 3.5 ml fractions are collected and the pH immediately adjusted to 7.4 with 1 M 
Tris-HC1 buffer, (pH 6.8). An aliquot from each fraction (50/tl) is analyzed on sodium dodecyl sulphate polyacrylamide gels [19] 
followed by silver staining [20]. The early fractions usually contain the beta subunit and later fractions contain the alpha subunit. 
Peak fractions containing Mol a and Mol# are pooled separately, and the protein precipitated by the addition of three volumes of 
acetone ( -  20 o C) for 12 h in a 15 ml Corex tube. The precipitate is collected by centrifugation at 10000 x g for 30 min at - 2 0  o C, 
and resuspended in 100-250 ~1 of buffer (1% (w/v) SDS, 20 mM N-ethylmorpholine acetate (pH 7.0) and 40 mM mercaptoethanol) 
with heating to 37°C for 5 min. Each sample is injected onto TSK 2000 (30 cm) and TSK 3000 (30 cm) columns in series, and the 
proteins resolved at a flow rate of 0.5 ml/min using the same buffer. Fractions containing the alpha and beta subunits of Mol are 
identified by absorbance at 280 nM and SDS polyacrylamide gel electrophoresis, pooled, and precipitated with acetone as above. 
10-20 /~g of the pure alpha or beta subunits can be generated during one purification procedure. Gp160-gp93 is purified from 
peritoneal guinea-pig granulocytes, as detailed elsewhere [15]. Briefly, the detergent- (0.5% NP40-) soluble granulocyte fraction is 
applied onto lentil lectin Sepharose as previously described [13]. The 0.1-M methyl a-mannoside-eluted fraction is applied onto 
anti-gpl60 monoclonal antibody-Sepharose column [15] and eluted with 0.2 M sodium citrate buffer (pH 3.5) containing 0.5% NP40. 
After neutralization the eluate, now containing dissociated gp160 and gp93, is applied onto anti-gp93 monoclonal antibody-Sep- 
harose [15]. Gp160, present in the drop through, is dialysed, lyophilized and precipitated in ethanol and the precipitate is resuspended 
in water. Preparations consisting of 22, 39 and 42 p.g of human Mol,~, 21 and 46 p.g of gp160 [21], each, in 30-60 #1 of 1% (w/v) 
SDS were submitted to 15-21 cycles of Edman degradation, using the Applied Biosystems Model 470 A sequencer. PTA derivatives 
were resolved via HPLC using an IBM Cyno column and Permaphase ETH precolumn, with gradient elution (solvent A: 70 mM 
sodium acetate (pH 5.5)/5% (v/v) tetrahydrofuran; solvent B: acetonitrile; gradient 11-48% B over 20 min, flow rate 1 ml/min). 
The sequences shown here were obtained. Multiple attempts to obtain sequence for Mol# and gp93 [15] were unsuccessful. The 
N-terminal sequence of mouse Mac-l~, was taken from Ref. 12. The single-letter notation for amino acids is used: A, Ala; D, Asp; E, 
Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; Z, Glx and Y, 
Tyr. 
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Fig. 2. Homologies between the N-termini of human Mola,  mouse LFA-la [12] and human platelet gp l Ib / I I Ia  [16]. Residues are 
aligned for the N-terminus, with the introduction of a gap between residues 7 and 8 in gpIIb/IIIa. In the right column are the 
percentage probabilities (P %) that homology is due only to chance, as determined by the sum of the values for each amino acid pair 
from the log odds matrix of Dayhnff. The score for the amino acid matching the gap position is zero [22]. 
a significant homology with the alpha subunits of 
two other membrane proteins that mediate cell 
adhesion, mouse LFA-1 [12] (P  value 0.1%) and 
human platelet glycoprotein l i b / I l i a  [16] (P  value 
0.25%) (Fig. 2). LFA-1 is involved in binding of 
lymphocytes to each other, [23] to their targets 
[24], or to endothelial cells [25]. Platelet l i b / I l i a  
glycoprotein complex acts as a receptor for 
fibronectin [26-29] and has a more general ad- 
hesion role serving also as a receptor for fibrino- 
gen [30,31] and for Von Willebrand factor 
[32,28,33]. Its function is inhibited by peptides 
related to the Arg-Gly-Asp-Ser sequence of 
fibronectin [28,34]. Mol is identical to CR3, a 
receptor for the complement C3 fragment, C3bi 
[6,7], and also has a more general adhesion func- 
tion, promoting adhesion of granulocytes to each 
other or to umbilical vein endothelial cell mono- 
layers [8,9]. Certain monoclonal antibodies di- 
rected against Mol also inhibit binding and inges- 
tion of fibronectin-coated microspheres by 
granulocytes and monocytes [35]. Furthermore, 
the co-expression of platelet l i b / I l i a ,  Mol and 
LFA-1 in cells transfected with a genomic clone 
[36], as well as subunit molecular mass similarities, 
strongly suggest that Mol may, in fact, be func- 
tionally and structurally homologous to the Arg- 
Gly-Asp-Ser receptor family of adhesion mole- 
cules. Although the tetrapeptide Arg-Gly-Asp-Ser 
does not inhibit the CR3 function of Mol  [37], its 
effect on Mol-dependent cell adhesion has not 
been evaluated. Further investigation into the 
structural basis for the cell-adhesion-promoting 
function of these cell-surface molecules should be 
of interest. 
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